ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2437

Autoantibodies from Sjögren’s Syndrome Enhance NLRP3 Inflammasome Activation and IL-18 Production in Human Salivary Gland Cell Line A-253

Cheng-Han Wu1, Ko Jen Li 2, Chia-Li Yu 3 and Song-Chou Hsieh 3, 1Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan (Republic of China), 2National Taiwan University Hospital, Taipei, Taiwan (Republic of China), 3Division of Immunology,Rheumatology and Allergy, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan (Republic of China)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoantibodies, IL-1/IL-18 and salivary gland, inflammasome activation, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary Sjögren’s syndrome (SS) is a chronic autoimmune epithelitis characterized by the presence of autoantibodies against SS-related antigen A (SSA) and lymphocytic infiltration of exocrine glands. The underlying mechanisms in the initiation and perpetuation of SS remain to be fully elucidated. Recently, the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome and pro-inflammatory cytokine Interleukin-18 (IL-18) have been implicated in the pathogenesis of SS. IL-18 serum concentrations were significantly higher in anti-SSA+ than in anti-SSA- SS patients and titers of anti-SSA antibodies were closely related with IL-18 protein levels. We hypothesized that immune complexes (ICs) containing anti-SSA antibodies (anti-SSA ICs) would lead to NLRP3 inflammasome activation and eventually to IL-18 production in an experimental model represented by the human salivary gland cell line A-253.

Methods: A-253 cells from human epidermoid carcinoma of the submaxillary gland were cultured. ICs were generated by incubation of cell culture supernatants (which contained released SSA autoantigens) with human anti-SSA antibody (OriGene Technologies, MD, USA), control human IgG and culture medium respectively for 1 hour and were stored at -80°C until used. A-253 cells were subjected to different stimulations for 4 hours. NLRP3, ASC, procaspase1 and IL-18 protein expression were measured by western blot and supernatant IL-18 level by enzyme-linked immunosorbent assay. Anti-SSA antibody and control human IgG were used at a final concentration of 80 ug/ml in all experiments. Results are presented as the mean ± S.D. The Student’s t-test was used for comparisons between two groups.

Results: A253 cells spontaneously released IL-18 and supernatant levels of IL-18 were significantly increased after stimulation with anti-SSA ICs, compared with control human IgG (p=0.021). Reactive oxygen species (ROS) scavengers, N-acetyl cysteine (NAC, 10mM), significantly decreased the secretion of IL-18 in each group (p < 0.05). More importantly, in the presence of NAC (10mM), anti-SSA ICs failed to induce IL-18 production from A-253 cells (p=0.19, compared to medium control). NLRP3 blockade by NAC were confirmed as NAC (25mM) treatment resulted in a marked decrease in the protein expression of the NLRP3 inflammasome and almost completely abolished the production of IL-18 from A-253 cells. Immunoprecipitation of NLRP3 was used to demonstrate that anti-SSA ICs potentiated coprecipitation of ASC and procaspase-1 proteins in A-253 cells. Furthermore, ICs containing anti-SSA antibodies and RNase A-digested cell culture supernatants (RNase A 100 ug/ml, incubation of 2 hours, for the removal of RNA from supernatants) decreased the amount of coprecipitated procaspase-1,secreted less IL-18 (p=0.02 compared to ICs containing no RNase A-digested supernatants) and lost the capacity to induce IL-18 production from A-253 cells (p=0.43, compared to medium control).

Conclusion: This novel study showed that ICs containing anti-SSA antibodies activated NLRP3 inflammasome and induced IL-18 secretion in A-253 cells. Endogenous RNA components of anti-SSA ICs and reactive oxygen species were responsible for this activation.

Effect of NAC and RNase A digestion of supernatants on anti-SSA ICs induced IL-18 production in A-253 cells.

Activation of the NLRP3 inflammasome by ICs containing anti-SSA antibodies.


Disclosure: C. Wu, None; K. Li, None; C. Yu, None; S. Hsieh, None.

To cite this abstract in AMA style:

Wu C, Li K, Yu C, Hsieh S. Autoantibodies from Sjögren’s Syndrome Enhance NLRP3 Inflammasome Activation and IL-18 Production in Human Salivary Gland Cell Line A-253 [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/autoantibodies-from-sjogrens-syndrome-enhance-nlrp3-inflammasome-activation-and-il-18-production-in-human-salivary-gland-cell-line-a-253/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantibodies-from-sjogrens-syndrome-enhance-nlrp3-inflammasome-activation-and-il-18-production-in-human-salivary-gland-cell-line-a-253/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology